Table 2. Clinicopathological characteristics in patients undergoing potentially curative surgery and adjuvant 5-FU chemotherapy for colorectal cancer (n=222) and survival.

	No adjuvant chemotherapy (n=172)		Adjuvant chemotherapy (n=50)
	HR (95% CI)	P-value	HR (95% CI)	P-value
Univariate analysis
Age (<65/65–74/⩾75) years	2.33 (1.48–3.68)	<0.001	0.73 (0.31–1.71)	0.464
Sex (male/female)	1.37 (0.77–2.46)	0.287	1.55 (0.55–4.36)	0.411
Site (colon/rectum)	1.23 (0.69–2.21)	0.477	1.19 (0.43–3.29)	0.735
Dukes stage (A/B/C)	1.75 (1.06–2.89)	0.029	3.36 (0.44–25.85)	0.245
C-reactive protein (⩽10, >10 mg l−1)	2.39 (1.32–4.34)	0.004	6.68 (2.05–21.72)	0.002
Albumin (⩾35/<35 g l−1)	1.42 (0.59–3.40)	0.433
Multivariate analysis
Age (<65/65–74/⩾75) years	1.87 (1.13–3.09)	0.015	1.21 (0.47–3.15)	0.693
Sex (male/female)	1.08 (0.55–2.09)	0.828	0.92 (0.26–3.22)	0.894
Site (colon/rectum)	1.57 (0.81–3.07)	0.185	1.15 (0.31–4.27)	0.834
Dukes stage (A/B/C)	1.39 (0.82–2.36)	0.219	2.56 (0.31–21.21)	0.384
C-reactive protein (⩽10, >10 mg l−1)	2.10 (1.04–4.25)	0.039	5.57 (1.32–23.51)	0.019
Albumin (⩾35/<35 g l−1)	1.18 (0.48–2.88)	0.721